Manulife Finl Co SEC Filings

Manulife Financial Corporation has reset the interest rate on its $2 billion principal amount of 3.375% Limited Recourse Capital Notes Series 1 for the five-year period starting June 19, 2026. The new rate will be 5.88300% per annum until June 19, 2031.

The rate reflects the Government of Canada Yield on June 18, 2026 plus a 2.839% spread, with interest continuing to be paid semi-annually on June 19 and December 19, beginning December 19, 2026. The Notes mature June 19, 2081 and are backed by 2,000,000 Non-Cumulative Fixed Rate Reset Class 1 Shares Series 27 held in a Limited Recourse Trust. Manulife may redeem the Notes, subject to regulatory approval, during a window around June 19, 2031 and every five years thereafter.

Manulife Financial Corporation announced the results of conversion elections for its Class 1 Preferred Shares, Series 3 and Series 4. Only 17,750 of the 6,537,903 outstanding Series 3 shares were elected to convert into Series 4, while 886,331 of the 1,462,097 outstanding Series 4 shares were elected to convert into Series 3.

Because fewer than 1,000,000 Series 4 shares would remain, Manulife will automatically convert all remaining Series 4 shares into Series 3 on June 19, 2026, and Series 3 holders will not be able to convert into Series 4. After this, Manulife will have 8,000,000 Series 3 preferred shares outstanding, listed on the Toronto Stock Exchange as MFC.PR.F.

For the five-year period from June 20, 2026 to June 19, 2031, Series 3 holders will receive fixed, non-cumulative quarterly dividends at an annual rate of 4.64000%, equal to $0.290000 per share per quarter, based on the five-year Government of Canada bond yield plus 1.41%.

Manulife Financial Corporation announced the results of conversion elections for its Class 1 Preferred Shares, Series 3 and Series 4. Only 17,750 of the 6,537,903 outstanding Series 3 shares were elected to convert into Series 4, while 886,331 of the 1,462,097 outstanding Series 4 shares were elected to convert into Series 3.

Because fewer than 1,000,000 Series 4 shares would remain, Manulife will automatically convert all remaining Series 4 shares into Series 3 on June 19, 2026, and Series 3 holders will not be able to convert into Series 4. After this, Manulife will have 8,000,000 Series 3 preferred shares outstanding, listed on the Toronto Stock Exchange as MFC.PR.F.

For the five-year period from June 20, 2026 to June 19, 2031, Series 3 holders will receive fixed, non-cumulative quarterly dividends at an annual rate of 4.64000%, equal to $0.290000 per share per quarter, based on the five-year Government of Canada bond yield plus 1.41%.

Manulife Financial Corporation is issuing S$500 million principal amount of 2.880% subordinated notes due June 4, 2036 in Singapore. These notes are structured to qualify as Tier 2 capital for Manulife.

The notes pay a fixed 2.880% rate until June 4, 2031, then reset to 0.931% over the prevailing five-year SORA OIS rate. Subject to prior approval from the Superintendent of Financial Institutions (Canada), Manulife may redeem the notes at par on June 4, 2031 and on any interest payment date after that, plus accrued interest. The subordinated notes rank equally with Manulife’s other subordinated indebtedness and have received in-principle approval for listing on the Singapore Exchange. The offering, made solely to non-U.S. persons under Regulation S, is expected to close on June 4, 2026 and will not be offered or sold in Canada or to Canadian residents.

Manulife Financial Corporation is issuing S$500 million principal amount of 2.880% subordinated notes due June 4, 2036 in Singapore. These notes are structured to qualify as Tier 2 capital for Manulife.

The notes pay a fixed 2.880% rate until June 4, 2031, then reset to 0.931% over the prevailing five-year SORA OIS rate. Subject to prior approval from the Superintendent of Financial Institutions (Canada), Manulife may redeem the notes at par on June 4, 2031 and on any interest payment date after that, plus accrued interest. The subordinated notes rank equally with Manulife’s other subordinated indebtedness and have received in-principle approval for listing on the Singapore Exchange. The offering, made solely to non-U.S. persons under Regulation S, is expected to close on June 4, 2026 and will not be offered or sold in Canada or to Canadian residents.

Manulife Financial Corporation has set new dividend rates for its preferred shares Series 3 and Series 4 effective June 20, 2026. Series 3 will pay a fixed dividend of 4.64000% per annum, or $0.290000 per share each quarter, until June 19, 2031. Series 4 will pay a floating dividend of 0.94092% for the first three‑month period to September 19, 2026, equal to 3.73300% annualized, or $0.235230 per share. Holders of Series 3 and Series 4 shares who wish to convert must instruct their broker by 5:00 p.m. Toronto time on June 4, 2026.

Manulife Financial Corporation has set new dividend rates for its preferred shares Series 3 and Series 4 effective June 20, 2026. Series 3 will pay a fixed dividend of 4.64000% per annum, or $0.290000 per share each quarter, until June 19, 2031. Series 4 will pay a floating dividend of 0.94092% for the first three‑month period to September 19, 2026, equal to 3.73300% annualized, or $0.235230 per share. Holders of Series 3 and Series 4 shares who wish to convert must instruct their broker by 5:00 p.m. Toronto time on June 4, 2026.

Manulife Financial Corporation reported shareholder voting results from its recent meeting. All nominated directors were elected, each receiving more than 95% of votes cast, with most nominees above 98% support.

Shareholders also approved the appointment of Ernst & Young LLP as auditors with 89.51% of votes for, and passed the advisory resolution on the company’s approach to executive compensation with 94.87% support.

Manulife Financial Corporation reported shareholder voting results from its recent meeting. All nominated directors were elected, each receiving more than 95% of votes cast, with most nominees above 98% support.

Shareholders also approved the appointment of Ernst & Young LLP as auditors with 89.51% of votes for, and passed the advisory resolution on the company’s approach to executive compensation with 94.87% support.

Manulife Financial reported a strong first quarter of 2026, with core earnings of $1.8 billion, up 8%, and net income attributed to shareholders of $1.1 billion, up $0.7 billion from a year earlier. Diluted core EPS rose to $1.06, an 11% increase, while reported EPS climbed to $0.65, up 178%. Core ROE reached 16.5% and the LICAT ratio stood at 136%, highlighting capital strength.

Insurance growth remained robust: APE sales grew 7% to $2.8 billion, new business CSM increased 16% to $1.0 billion, and new business value rose 7% to $944 million. Asia drove much of this momentum with 22% core earnings growth and 15% NBV growth, while Canada and the U.S. saw mixed results as Canada’s core earnings declined and U.S. core earnings dipped modestly despite a swing to positive net income.

Global Wealth and Asset Management delivered higher fees and a better core EBITDA margin but recorded $4.4 billion of net outflows compared with prior-year inflows. Manulife continued to execute on strategic initiatives, completing the Schroders Indonesia acquisition, entering a partnership with L&G, and scaling AI tools across businesses. The board declared a quarterly common dividend of $0.485 per share, payable on June 19 2026, with dividends eligible for reinvestment through existing Canadian and U.S. plans.

Manulife Financial reported a strong first quarter of 2026, with core earnings of $1.8 billion, up 8%, and net income attributed to shareholders of $1.1 billion, up $0.7 billion from a year earlier. Diluted core EPS rose to $1.06, an 11% increase, while reported EPS climbed to $0.65, up 178%. Core ROE reached 16.5% and the LICAT ratio stood at 136%, highlighting capital strength.

Insurance growth remained robust: APE sales grew 7% to $2.8 billion, new business CSM increased 16% to $1.0 billion, and new business value rose 7% to $944 million. Asia drove much of this momentum with 22% core earnings growth and 15% NBV growth, while Canada and the U.S. saw mixed results as Canada’s core earnings declined and U.S. core earnings dipped modestly despite a swing to positive net income.

Global Wealth and Asset Management delivered higher fees and a better core EBITDA margin but recorded $4.4 billion of net outflows compared with prior-year inflows. Manulife continued to execute on strategic initiatives, completing the Schroders Indonesia acquisition, entering a partnership with L&G, and scaling AI tools across businesses. The board declared a quarterly common dividend of $0.485 per share, payable on June 19 2026, with dividends eligible for reinvestment through existing Canadian and U.S. plans.

Manulife Financial Corporation reported strong results for the quarter ended March 31, 2026, with net income attributed to shareholders of $1.15 billion, up from $485 million a year earlier. Core earnings rose to $1.84 billion, an 8% increase on a constant exchange rate basis, reflecting business growth, favourable actuarial updates and better insurance experience, partly offset by lower investment spreads and higher expenses.

Diluted core EPS grew 11% to $1.06, while reported EPS climbed to $0.65, up 178%. Core ROE improved to 16.5% and ROE to 10.1%. Insurance momentum remained solid, with APE sales up 7%, new business contractual service margin up 16%, and new business value up 7%, led by double‑digit growth in Asia and stronger U.S. accumulation products.

Global Wealth and Asset Management generated higher fee-based core earnings and a 29.0% core EBITDA margin but saw net outflows of $4.4 billion versus prior-year inflows. Capital strength stayed robust with a LICAT ratio of 136% at MLI, a lower financial leverage ratio of 22.5%, and book value per common share rising to $26.30. The company returned $1.2 billion to shareholders through dividends and buybacks, completed the Schroders Indonesia acquisition, entered a strategic partnership with L&G, and advanced multiple AI and health-focused initiatives across regions.

Manulife Financial Corporation reported strong results for the quarter ended March 31, 2026, with net income attributed to shareholders of $1.15 billion, up from $485 million a year earlier. Core earnings rose to $1.84 billion, an 8% increase on a constant exchange rate basis, reflecting business growth, favourable actuarial updates and better insurance experience, partly offset by lower investment spreads and higher expenses.

Diluted core EPS grew 11% to $1.06, while reported EPS climbed to $0.65, up 178%. Core ROE improved to 16.5% and ROE to 10.1%. Insurance momentum remained solid, with APE sales up 7%, new business contractual service margin up 16%, and new business value up 7%, led by double‑digit growth in Asia and stronger U.S. accumulation products.

Global Wealth and Asset Management generated higher fee-based core earnings and a 29.0% core EBITDA margin but saw net outflows of $4.4 billion versus prior-year inflows. Capital strength stayed robust with a LICAT ratio of 136% at MLI, a lower financial leverage ratio of 22.5%, and book value per common share rising to $26.30. The company returned $1.2 billion to shareholders through dividends and buybacks, completed the Schroders Indonesia acquisition, entered a strategic partnership with L&G, and advanced multiple AI and health-focused initiatives across regions.

Manulife Financial Corporation filed an amended Form 6-K to replace a prior version and correct clerical errors, attaching an updated news release. The release states Manulife will not redeem its outstanding Series 3 and Series 4 Class 1 preferred shares on June 19, 2026, preserving investor holdings.

Holders of the 6,537,903 Series 3 Preferred Shares and 1,462,097 Series 4 Preferred Shares may elect to convert between the two series on a one-for-one basis on June 19, 2026, subject to minimum outstanding thresholds of 1,000,000 shares per series. Deadlines, automatic conversion conditions and future dividend reset dates and announcement timing are detailed for investors.

Manulife Financial Corporation filed an amended Form 6-K to replace a prior version and correct clerical errors, attaching an updated news release. The release states Manulife will not redeem its outstanding Series 3 and Series 4 Class 1 preferred shares on June 19, 2026, preserving investor holdings.

Holders of the 6,537,903 Series 3 Preferred Shares and 1,462,097 Series 4 Preferred Shares may elect to convert between the two series on a one-for-one basis on June 19, 2026, subject to minimum outstanding thresholds of 1,000,000 shares per series. Deadlines, automatic conversion conditions and future dividend reset dates and announcement timing are detailed for investors.

Manulife Financial Corporation is leaving its preferred share capital structure unchanged in 2026 and will not redeem its outstanding Series 3 or Series 4 Class 1 Preferred Shares on June 19, 2026. Instead, holders of the 6,537,903 Series 3 and 1,462,097 Series 4 shares may choose to convert all or part of their holdings into the other series on a one-for-one basis on that date.

Beneficial owners who wish to convert must instruct their broker by 5:00 p.m. Toronto time on June 4, 2026. If, after that date, either series would have fewer than 1,000,000 shares outstanding, all remaining shares of that small series will automatically convert into the other series on June 19, 2026. New dividend rates for Series 3 (for June 20, 2026–June 19, 2031) and Series 4 (for June 20–September 19, 2026) will be announced on May 21, 2026.

Manulife Financial Corporation is leaving its preferred share capital structure unchanged in 2026 and will not redeem its outstanding Series 3 or Series 4 Class 1 Preferred Shares on June 19, 2026. Instead, holders of the 6,537,903 Series 3 and 1,462,097 Series 4 shares may choose to convert all or part of their holdings into the other series on a one-for-one basis on that date.

Beneficial owners who wish to convert must instruct their broker by 5:00 p.m. Toronto time on June 4, 2026. If, after that date, either series would have fewer than 1,000,000 shares outstanding, all remaining shares of that small series will automatically convert into the other series on June 19, 2026. New dividend rates for Series 3 (for June 20, 2026–June 19, 2031) and Series 4 (for June 20–September 19, 2026) will be announced on May 21, 2026.

Manulife Financial Corporation filed an independent auditor’s report covering its consolidated financial statements for the years ended December 31, 2025 and 2024. The auditors conclude that the statements present fairly the company’s financial position and performance in accordance with IFRS.

The report highlights key audit matters, including the valuation of $541 billion of insurance contract liabilities and $95.3 billion of Level 3 invested assets that rely on complex models and non-observable inputs. It also focuses on IFRS 9 hedge accounting, where Manulife recorded changes in value of hedged assets of $338 million and hedged liabilities of $1,180 million in 2025.

The auditors describe extensive testing of controls, models, and assumptions, and note they have nothing to report regarding inconsistencies in accompanying management discussion and other information reviewed to date.

Manulife Financial Corporation filed an independent auditor’s report covering its consolidated financial statements for the years ended December 31, 2025 and 2024. The auditors conclude that the statements present fairly the company’s financial position and performance in accordance with IFRS.

The report highlights key audit matters, including the valuation of $541 billion of insurance contract liabilities and $95.3 billion of Level 3 invested assets that rely on complex models and non-observable inputs. It also focuses on IFRS 9 hedge accounting, where Manulife recorded changes in value of hedged assets of $338 million and hedged liabilities of $1,180 million in 2025.

The auditors describe extensive testing of controls, models, and assumptions, and note they have nothing to report regarding inconsistencies in accompanying management discussion and other information reviewed to date.